Zacks Investment Research on MSN

Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains

Shares of Abbott ABT have edged up 0.7% since the company’s third-quarter 2025 earnings release on Oct. 15, 2025. The company ...
Medical Device Network on MSN

Abbott’s strong Q3 medtech performance offset by diagnostic weakness

Abbott narrowly missed analysts’ expectations of $11.4bn for Q3 2025, with diminished Covid-19 test demand and China ...

Abbott signals confidence in sustaining high single-digit sales and double-digit EPS growth into 2026, led by innovation and new product launches

Get key Q3 2025 earnings insights for Abbott Labs (ABT)—discover growth drivers, innovation highlights, and outlook for 2026.
Medscape

Novel Point-of-Care Troponin Assay May Facilitate Faster Rule-Out of AMI

A new point-of-care troponin assay can safely rule out acute myocardial infarction (AMI) in just 15 minutes in a large proportion of patients with symptoms suggestive of acute coronary syndrome, ...
Reuters

Abbott Labs: General Electric confirms it will acquires Abbott's in vitro and Point-of-Care Diagnostics Businesses for $8.13 bln

General Electric (GE) and ABT confirm that GE will acquire ABT's primary in vitro diagnostics businesses and Abbott Point-of-Care diagnostics business for $8.13 blnin cash. ABT's Molecular Diagnostics ...